- Superior product, including automation features and shift to a SaaS model
- Opportunity to support the Company’s transformation to a platform player by developing best-in-class software that uses cutting edge AI technology to automate workflows
- Increasing efficiency and reducing overall costs for the global pharma customer
- Strong ESG agenda promoting the use of AI and machine-learning to increase productivity, bring new drugs to market, and ensure secure data stewardship
The visionary Company has successfully developed a next-generation technology platform that uses advanced cognitive computing and machine learning. More than 500 life sciences companies, CROs and government health authorities around the world rely on ArisGlobal’s software to accomplish mission-critical tasks throughout the drug development process.
Nordic Capital partnered with the founding family in 2019. The common goals were to accelerate ArisGlobal’s growth and provide better environmental health, social equity and economic vitality for future generations. A supplementary investment was made in 2021, when Nordic Capital acquired an additional shareholding from the founding family. Since then, the Company has benefited from continued investments in Research and Development, cognitive computing capabilities, global delivery, sustainable operations, and commercial excellence.
Technology & Payments
EUR 130 million
Fund IX, Fund X
Miami, FL, USA